Mncm.org
Help and Healing: Depression resources for care and recovery
Depression Fact Sheet
Major Depression
What is major depression?
Major depression is a serious medical illness affecting 15 million American adults, or approximately 5 to 8 percent of the adult population in a given year. Unlike normal emotional experiences of sadness, loss, or passing mood states, major depression is
persistent and can significantly interfere with an individual's thoughts, behavior, mood, activity, and physical health. Among all medical illnesses, major depression is the leading cause of disability in the U.S. and many other developed countries.
Depression occurs twice as frequently in women as in men, for reasons that are not fully understood. More than half of those who experience a single episode of depression will continue to have episodes that occur as frequently as once or even twice a year. Without treatment, the frequency of depressive illness as well as the severity of symptoms tends to increase over time. Left untreated, depression can lead to suicide.
The road to recovery
Major depression, also known as clinical depression or unipolar depression,
is only one type of depressive disorder. Other depressive disorders include
Help and Healing connects you to quality
dysthymia (chronic, less severe depression) and bipolar depression (the de-
resources for depression care and recovery.
pressed phase of bipolar disorder or manic depression). People who have
Get better, faster.
bipolar disorder experience both depression and mania. Mania involves un-
usually and persistently elevated mood or irritability, elevated self-esteem, and excessive energy, thoughts, and talking.
What are the symptoms of major depression?
The onset of the first episode of major depression may not be obvious if it is gradual or mild. The symptoms of major depression characteristically represent a significant change from how a person functioned before the illness. The symptoms of depression include:
• persistently sad or irritable mood • pronounced changes in sleep, appetite, and energy • difficulty thinking, concentrating, and remembering • physical slowing or agitation • lack of interest in or pleasure from activities that were once enjoyed • feelings of guilt, worthlessness, hopelessness, and emptiness • recurrent thoughts of death or suicide • persistent physical symptoms that do not respond to treatment, such as headaches, digestive disorders,
Help and Healing: Depression resources for care and recovery
Section 1: Identification, Education and Talking Points
When several of these symptoms of depressive illness occur at the same time, last
longer than two weeks, and interfere with ordinary functioning, professional treatment is needed.
What are the causes of major depression?
There is no single cause of major depression. Psychological, biological, and environmental factors may all contribute to its development. Whatever the specific causes of depression, scientific research has firmly established that major depression is a biological, medical illness.
Norepinephrine, serotonin, and dopamine are three neurotransmitters (chemical messengers that transmit electrical signals between brain cells) thought to be involved with major depression. Scientists believe that if there is a chemical imbalance in these neurotransmitters, then clinical states of depression result. Antide-pressant medications work by increasing the availability of neurotransmitters or by changing the sensitivity of the receptors for these chemical messengers.
Scientists have also found evidence of a genetic predisposition to major depression. There is an increased risk for developing depression when there is a family history of the illness. Not everyone with a genetic predisposition develops depression, but some people probably have a biological make-up that leaves them particularly vulnerable to developing depression. Life events, such as the death of a loved one, a major loss or change, chronic stress, and alcohol and drug abuse, may trigger episodes of depression. Some illnesses such as heart disease and cancer and some medications may also trigger depressive episodes. It is also important to note that many depressive episodes occur spontaneously and are not triggered by a life crisis, physical illness, or other risks.
How is major depression treated?
Although major depression can be a devastating illness, it is highly treatable. Between 80 and 90 percent of those diagnosed with major depression can be effectively treated and return to their usual daily activities and feelings. Many types of treatment are available, and the type chosen depends on the individual and the severity and patterns of his or her illness. There are three well-established types of treatment for depression: medications, psychotherapy, and electroconvulsive therapy (ECT). For some people who have a seasonal component to their depression, light therapy may be useful. These treatments may be used alone or in combination. Additionally, peer education and support can promote recovery. Attention to lifestyle, including diet, exercise, and smoking cessation, can result in better health, including mental health.
Medication. It often takes two to four weeks for antidepressants to start having an effect, and 6-12 weeks for antidepressants to have their full effect. The first antidepressant medications were introduced in the 1950s. Research has shown that imbalances in neurotransmitters like serotonin, dopamine, and norepi-nephrine can be corrected with antidepressants. Four groups of antidepressant medications are most often prescribed for depression:
Help and Healing: Depression resources for care and recovery
Section 1: Identification, Education and Talking Points
Selective serotonin reuptake inhibitors (SSRIs) act specifically on the neurotrans-
mitter serotonin. They are the most common agents prescribed for depression worldwide. These agents block the reuptake of serotonin from the synapse to the nerve, thus artificially increasing the serotonin that is available in the synapse (this is functional serotonin, since it can become involved in signal transmission, the cardinal function of neurotransmitters). SSRIs include fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa), escitalopram (Lexapro), and fluvoxamine (Luvox).
Serotonin and norepinephrine reuptake inhibitors (SNRIs) are the second-most popular antidepressants
worldwide. These agents block the reuptake of both serotonin and norepinephrine from the synapse into
the nerve (thus increasing the amounts of these chemicals that can participate in signal transmission). SNRIs
include venlafaxine (Effexor) and duloxetine (Cymbalta).
Bupropion (Wellbutrin) is a very popular antidepressant medication classified as a norepinephrine-dopamine
reuptake inhibitor (NDRI). It acts by blocking the reuptake of dopamine and norepinephrine.
Mirtazapine (Remeron) works differently from the compounds discussed above. Mirtazapine targets specific
serotonin and norepinephrine receptors in the brain, thus indirectly increasing the activity of several brain circuits.
Tricyclic antidepressants (TCAs) are older agents seldom used now as first-line treatment. They work similarly to
the SNRIs, but have other neurochemical properties which result in very high side effect rates, as compared to almost
all other antidepressants. They are sometimes used in cases where other antidepressants have not worked. TCAs
include amitriptyline (Elavil, Limbitrol), desipramine (Norpramin), doxepin (Sinequan), imipramine (Norpramin,
Tofranil), nortriptyline (Pamelor, Aventyl), and protriptyline (Vivactil).
Monoamine oxidase inhibitors (MAOIs) are also seldom used now. They work by inactivating enzymes in the
brain which catabolize (chew up) serotonin, norepinephrine, and dopamine from the synapse, thus increasing the
levels of these chemicals in the brain. They can sometimes be effective for people who do not respond to other
medications or who have "atypical" depression with marked anxiety, excessive sleeping, irritability, hypochondria,
or phobic characteristics. However, they are the least safe antidepressants to use, as they have important medication
interactions and require adherence to a particular diet. MAOIs include phenelzine (Nardil), isocarboxazid (Marplan),
and tranylcypromine sulfate (Parnate).
Non-antidepressant adjunctive agents. Often psychiatrists will combine the antidepressants mentioned above
with each other (we call this a "combination") or with agents which are not antidepressants themselves (we call
this "augmentation"). These latter agents can include the atypical antipsychotic agents [aripiprazole (Abilify),
olanzapine (Zyprexa), quetiapine (Seroquel), ziprasidone (Geodon), risperidone (Risperdal)], buspirone (Buspar),
thyroid hormone (triiodothyonine, or "T3"), the stimulants [methylphenidate (Ritalin), dextroaphetamine (Aderal )],
dopamine receptor agonists [pramipexole (Mirapex), ropinirole (Requipp)], lithium, lamotrigine (Lamictal),
s-adenosyl methionine (SAMe), pindolol, and steroid hormones (testosterone, estrogen,DHEA).
Consumers and their families must be cautious during the early stages of medication treatment because normal energy levels and the ability to take action often return before mood improves. At this time - when decisions are easier to make, but depression is still severe - the risk of suicide may temporarily increase.
Help and Healing: Depression resources for care and recovery
Section 1: Identification, Education and Talking Points
Psychotherapy. There are several types of psychotherapy that have been
shown to be effective for depression including cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT). Research has shown that mild to moderate depression can often be treated successfully with either of these therapies used alone. However, severe depression appears more likely to respond to a combina-tion of psychotherapy and medication.
Cognitive-behavioral therapy (CBT)
– helps to change the negative thinking and unsatisfying
behavior associated with depression, while teaching people how to unlearn the behavioral patterns that
contribute to their illness.
Interpersonal therapy (IPT)
– focuses on improving troubled personal relationships and on
adapting to new life roles that may have been associated with a person's depression.
Electroconvulsive therapy (ECT). ECT is a highly effective treatment for severe depressive epi-sodes. In situations where medication, psychotherapy, and a combination of the two prove ineffective, or work too slowly to relieve severe symptoms such as psychosis or thoughts of suicide, ECT may be considered. ECT may also be considered for those who for one reason or another cannot take antidepressant medications.
What are the side effects of the medications used to treat depression?
Different medications produce different side effects, and people differ in the type and severity of side effect they experience. About 50 percent of people who take antidepressant medications experience some side effects, par-ticularly during the first weeks of treatment. Side effects that are particularly bothersome can often be treated by changing the dose of the medication, switching to a different medication, or treating the side effect directly with additional medications. Rarely, serious side effects such as fainting, heart problems, or seizure may occur, but they are almost always treatable.
Source: http://mncm.org/wp-content/uploads/2014/09/HelpandHealing_Sec1_DepressionFactSheet.pdf
Acta Anaesthesiol Scand 2008; 52: 897–907 r 2008 The Authors Printed in Singapore. All rights reserved Journal compilation r 2008 The Acta Anaesthesiologica Scandinavica Foundation ACTA ANAESTHESIOLOGICA SCANDINAVICA Pre-hospital airway management: guidelines from a taskforce from the Scandinavian Society for Anaesthesiologyand Intensive Care Medicine ERLAC , P. K. HYLDMO , P. KONGSTAD , J. KUROLA , A. R. NAKSTAD and M. SANDBERG
JBC Papers in Press. Published on September 16, 2010 as Manuscript M110.126789 OXIDATIVE AND NITROSATIVE MODIFICATIONS OF TROPOELASTIN PREVENT ELASTIC FIBER ASSEMBLY IN VITRO* Kamal Akhtar1, Thomas J. Broekelmann2, Ming Miao3, Fred W. Keeley3, Barry C. Starcher4, Richard A. Pierce1, Robert P. Mecham1,2, and Tracy L. Adair-Kirk1